Celltrion cruising to launch Truxima with nullifying relevant patents in Korea
Celltrion announced the Intellectual Property Tribunal ruled patent nullification related to an original ‘Rituxan’ patent owned by Biogen on the 23rd of August.
In order to commercialize a Rituxan’s(Mabthera) biosimilar, ‘Truxima,’ Celltrion has once applied for a patent nullification suit on pa...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
